Vistagen Therapeutics, Inc. — Form 10-Q Summary
Reporting period: Three months ended June 30, 2014 (the first quarter of fiscal 2015), compared with the three months ended June 30, 2013. The filing is unaudited. The company develops stem-cell-based drug discovery and safety-testing technologies and drug-rescue programs; it reported no revenue in either quarter.
Financial performance and position
| Metric | Quarter ended June 30, 2014 | Prior-year quarter |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $473,600 | $695,500 |
| General and administrative expense | $797,200 | $604,600 |
| Operating loss | $(1,270,800) | $(1,300,100) |
| Net income (loss) | $(4,553,300) | $185,700 |
| Net cash used in operations | $(1,011,800) | $(731,800) |
| Cash at period end | $400,700 | $89,800 |
- At June 30, 2014, total assets were $764,700, total liabilities were $16,155,300, and stockholders’ deficit was $15,390,600. Current assets of $554,600 were substantially below current liabilities of $6,196,600.
- Liabilities included a $4,701,200 warrant liability, up from $2,973,900 at March 31, 2014, and substantial notes payable. The warrant remeasurement is non-cash and contributed $1,727,200 of expense for the quarter.
- Interest expense, net, was $784,900, versus $316,400. The company also recorded a $768,000 loss on extinguishment of debt, principally related to note and warrant amendments and a settlement with Icahn School of Medicine at Mount Sinai.
- Cash provided by financing activities was $1,412,500, primarily from securities issuance; the quarter-end cash balance increased from zero at the start of the quarter.
Material changes versus the prior-year quarter
- Net results swung from $185,700 of income to a $4.55 million loss. The change chiefly reflects the warrant-liability expense, higher interest expense and debt-extinguishment charges; operating loss was slightly lower.
- R&D expense declined 32%, mainly reflecting lower sponsored research and technology-license costs. G&A increased 32%, largely due to higher legal, accounting and professional fees, including strategic advisory services.
- Operating cash use increased from $731,800 to $1,011,800. Management said it was limiting cash commitments and expenditures amid working-capital constraints.
- During the quarter, the company raised $1.57 million in private-placement units, each including a 10% convertible note, common shares and warrants. Many 2013/2014 notes and warrants were amended, including extending certain note maturities to March 31, 2015.
Outlook, risks and unusual items
- Liquidity and going concern: Management stated that $400,700 of quarter-end cash was insufficient to fund planned operations. It estimated approximately $7.5 million of cash needs over the next 12–15 months and disclosed recurring losses and negative operating cash flows. The statements assume going concern, but management warned that failure to obtain substantial financing could require cuts or deferrals to R&D and could threaten the company’s ability to continue as a going concern.
- Financing dependence: Autilion AG remained in default under an agreement to invest up to $36 million; it had completed only a nominal initial closing, and further funding was uncertain. The company’s public-offering registration statement covering up to 30 million shares and warrants was declared effective August 7, 2014, but completion and proceeds were not assured. The company also reported $55,000 of additional private-placement proceeds through August 8.
- Platinum notes: A July 2014 agreement conditionally provided for conversion of approximately $4.1 million of Platinum senior secured notes if specified financing thresholds were met by August 31, 2014. A public offering raising at least $10 million could result in conversion into newly created Series B preferred stock; a qualifying private financing could result in common-stock conversion. The arrangement could reduce cash repayment needs, but depends on financing completion.
- Business outlook: No revenue or earnings guidance was provided. Management said it was prepared to launch multiple CardioSafe 3D drug-rescue programs subject to sufficient financing. AV-101 had completed Phase 1 clinical development; further development or commercialization opportunities remained prospective.
- Other notable matters: The board authorized a one-for-twenty reverse stock split in July 2014, which was not yet effective as of the filing. Management identified financing availability, clinical and nonclinical results, regulatory requirements, competition and potential dilution as material risks. It reported no legal proceedings and no off-balance-sheet arrangements.
Key facts for investors to verify
- Whether the public offering, Autilion financing or other funding was completed, and the resulting cash runway and dilution.
- Whether the conditional Platinum note conversion occurred, including the amount and class of securities issued and release of collateral interests.
- Current cash burn, near-term debt maturities and any subsequent changes to vendor or note-payment terms.
- Progress and funding requirements for CardioSafe 3D, LiverSafe 3D and any drug-rescue programs, as well as plans for AV-101.
- Effectiveness and terms of the proposed reverse split and any changes to share and warrant counts.